{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:21:24Z","timestamp":1788394884318,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-026-03840-8","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T13:46:32Z","timestamp":1782135992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety, tolerability, pharmacokinetics, and pharmacodynamics of ABP-671 in healthy participants and patients with hyperuricemia and gout: a proof-of-concept study"],"prefix":"10.1186","volume":"28","author":[{"given":"Jin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ullrich","family":"Schwertschlag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam W.","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"3840_CR1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/rheumatology\/kez203","volume":"58","author":"T Pascart","year":"2019","unstructured":"Pascart T, Liote F. Gout: state of the art after a decade of developments. Rheumatology (Oxford). 2019;58:27\u201344.","journal-title":"Rheumatology (Oxford)"},{"key":"3840_CR2","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","volume":"388","author":"N Dalbeth","year":"2016","unstructured":"Dalbeth N, Merriman TR, Stamp LK. Gout Lancet. 2016;388:2039\u201352.","journal-title":"Gout Lancet"},{"key":"3840_CR3","doi-asserted-by":"publisher","first-page":"ITC1","DOI":"10.7326\/AITC201607050","volume":"165","author":"T Neogi","year":"2016","unstructured":"Neogi T, Gout. Ann Intern Med. 2016;165:ITC1\u201316.","journal-title":"Ann Intern Med"},{"key":"3840_CR4","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","volume":"397","author":"N Dalbeth","year":"2021","unstructured":"Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout Lancet. 2021;397:1843\u201355.","journal-title":"Gout Lancet"},{"key":"3840_CR5","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","volume":"16","author":"M Dehlin","year":"2020","unstructured":"Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16:380\u201390.","journal-title":"Nat Rev Rheumatol"},{"key":"3840_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","volume":"11","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11:649\u201362.","journal-title":"Nat Rev Rheumatol"},{"key":"3840_CR7","first-page":"1","volume":"2015","author":"R Liu","year":"2015","unstructured":"Liu R, Han C, Wu D, Xia X, Gu J, Guan H, et al. Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis. Biomed Res Int. 2015;2015:1\u201312.","journal-title":"Biomed Res Int"},{"key":"3840_CR8","first-page":"533","volume":"102","author":"KT Clebak","year":"2020","unstructured":"Clebak KT, Morrison A, Croad JR, Gout. Rapid Evid Rev Am Fam Physician. 2020;102:533\u20138.","journal-title":"Rapid Evid Rev Am Fam Physician"},{"key":"3840_CR9","doi-asserted-by":"publisher","first-page":"1008598","DOI":"10.3389\/fpubh.2022.1008598","volume":"10","author":"B Zhu","year":"2022","unstructured":"Zhu B, Wang Y, Zhou W, Jin S, Shen Z, Zhang H, et al. Trend dynamics of gout prevalence among the Chinese population, 1990\u20132019: A joinpoint and age-period-cohort analysis. Front Public Health. 2022;10:1008598.","journal-title":"Front Public Health"},{"key":"3840_CR10","first-page":"CD010039","volume":"2013","author":"JH Moi","year":"2013","unstructured":"Moi JH, Sriranganathan MK, Edwards CJ, Buchbinder R. Lifestyle interventions for chronic gout. Cochrane Database Syst Rev. 2013;2013:CD010039.","journal-title":"Cochrane Database Syst Rev"},{"key":"3840_CR11","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/art.41247","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol. 2020;72:879\u201395.","journal-title":"Arthritis Rheumatol"},{"key":"3840_CR12","doi-asserted-by":"crossref","unstructured":"Neilson J, Bonnon A, Dickson A, Roddy E. Gout: diagnosis and management\u2014summary of NICE guidance. BMJ. 2022.","DOI":"10.1136\/bmj.o1754"},{"key":"3840_CR13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/BOR.0000000000000861","volume":"34","author":"Y Afinogenova","year":"2022","unstructured":"Afinogenova Y, Danve A, Neogi T. Update on gout management: what is old and what is new. Curr Opin Rheumatol. 2022;34:118\u201324.","journal-title":"Curr Opin Rheumatol"},{"key":"3840_CR14","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/j.semarthrit.2020.04.010","volume":"50","author":"MH Pillinger","year":"2020","unstructured":"Pillinger MH, Mandell BF. Therapeutic approaches in the treatment of gout. Semin Arthritis Rheum. 2020;50:S24\u201330.","journal-title":"Semin Arthritis Rheum"},{"key":"3840_CR15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.amjmed.2018.12.010","volume":"132","author":"MV Perez-Gomez","year":"2019","unstructured":"Perez-Gomez MV, Bartsch LA, Castillo-Rodriguez E, Fernandez-Prado R, Kanbay M, Ortiz A. Potential Dangers of Serum Urate-Lowering Therapy. Am J Med. 2019;132:457\u201367.","journal-title":"Am J Med"},{"key":"3840_CR16","doi-asserted-by":"publisher","first-page":"925219","DOI":"10.3389\/fphar.2022.925219","volume":"13","author":"C Jenkins","year":"2022","unstructured":"Jenkins C, Hwang JH, Kopp JB, Winkler CA, Cho SK. Review of Urate-Lowering Therapeutics: From the Past to the Future. Front Pharmacol. 2022;13:925219.","journal-title":"Front Pharmacol"},{"key":"3840_CR17","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/14656566.2021.1918102","volume":"22","author":"T Ishikawa","year":"2021","unstructured":"Ishikawa T, Takahashi T, Taniguchi T, Hosoya T. Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout. Expert Opin Pharmacother. 2021;22:1397\u2013406.","journal-title":"Expert Opin Pharmacother"},{"key":"3840_CR18","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","volume":"31","author":"M Lee","year":"2008","unstructured":"Lee M, Graham G, Williams K, Day R. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf. 2008;31:643\u201365.","journal-title":"Drug Saf"},{"key":"3840_CR19","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1080\/14397595.2018.1538003","volume":"29","author":"D Fitz-Patrick","year":"2018","unstructured":"Fitz-Patrick D, Roberson K, Niwa K, Fujimura T, Mori K, Hall J, et al. Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and\/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials. Mod Rheumatol. 2018;29:1042\u201352.","journal-title":"Mod Rheumatol"},{"key":"3840_CR20","doi-asserted-by":"crossref","unstructured":"Motoki K, Igarashi T, Omura K, Nakatani H, Iwanaga T, Tamai I, et al. Pharmacokinetic\/pharmacodynamic modeling and simulation of dotinurad, a novel uricosuric agent, in healthy volunteers. Volume 7. Pharmacology Research & Perspectives; 2019.","DOI":"10.1002\/prp2.533"},{"key":"3840_CR21","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3899\/jrheum.161062","volume":"44","author":"AS Steinberg","year":"2017","unstructured":"Steinberg AS, Vince BD, Choi Y-J, Martin RL, McWherter CA, Boudes PF. The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout. J Rhuematol. 2017;44:374\u20139.","journal-title":"J Rhuematol"},{"key":"3840_CR22","doi-asserted-by":"publisher","first-page":"5738900","DOI":"10.1155\/2021\/5738900","volume":"2021","author":"Y Chen","year":"2021","unstructured":"Chen Y, You R, Wang K, Wang Y. Recent Updates of Natural and Synthetic URAT1 Inhibitors and Novel Screening Methods. Evid Based Complement Alternat Med. 2021;2021:5738900.","journal-title":"Evid Based Complement Alternat Med"},{"key":"3840_CR23","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1002\/art.40159","volume":"69","author":"N Dalbeth","year":"2017","unstructured":"Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis Rheumatol. 2017;69:1903\u201313.","journal-title":"Arthritis Rheumatol"},{"key":"3840_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s10157-019-01802-w","volume":"24","author":"T Hosoya","year":"2020","unstructured":"Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study. Clin Exp Nephrol. 2020;24:44\u201352.","journal-title":"Clin Exp Nephrol"},{"key":"3840_CR25","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.1093\/rheumatology\/keab198","volume":"60","author":"Y Lin","year":"2021","unstructured":"Lin Y, Chen X, Ding H, Ye P, Gu J, Wang X, et al. Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study. Rheumatology (Oxford). 2021;60:5089\u201397.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-026-03840-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03840-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03840-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:09:04Z","timestamp":1788394144000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-026-03840-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3840"],"URL":"https:\/\/doi.org\/10.1186\/s13075-026-03840-8","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"6 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was obtained from the ethics committee of Xuanwu Hospital of Capital Medical University (No. [2021]003). All participants signed the informed consent form before enrollment.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ullrich Schwertschlag, Jingfei Li, Yan Yang, Adam W. Jin, Roy J. Wu, Dongfang Shi are employees of Atom Therapeutics Co., Ltd. Other authors declared no conflict of interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"162"}}